Shereen Solaiman, Chief People Officer of Myriad Genetics Inc, filed a statement of changes in beneficial ownership on November 9, 2026, disclosing a grant of 83,049 time-based stock options on November 6, 2026.

Key Highlights

  • Reporting person: Shereen Solaiman, identified as Chief People Officer of Myriad Genetics Inc (NASDAQ:MYGN).
  • Option grant: 83,049 non-qualified stock options acquired on November 6, 2026, with a transaction code of A (acquired).
  • Exercise price: $5.92 per share, described in the filing as equal to the closing price of the issuer's common stock on the grant date.
  • Vesting schedule: Options vest in full on November 6, 2029, subject to continued service through that date.
  • Expiration date: November 6, 2036, as stated in Table II of the filing.
  • Award type: Described as "a one-time non-qualified stock option granted as a retention award" under Myriad Genetics' 2026 Employee, Director and Consultant Equity Incentive Plan.
  • Post-transaction holdings: 83,049 derivative securities beneficially owned following the reported transaction, held directly.

Retention Option Award to Myriad Genetics Chief People Officer

According to the filing, Myriad Genetics Inc, a molecular diagnostics company listed on NASDAQ:MYGN, granted its Chief People Officer, Shereen Solaiman, a one-time retention award in the form of non-qualified stock options. The grant was made on November 6, 2026, under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. The filing describes the award as a retention instrument, meaning it is structured to encourage the reporting person's continued service through the vesting date.

The filing specifies that the options cover 83,049 shares of Myriad Genetics common stock, with an exercise price of $5.92 per share. Per the footnotes, that price equals the closing market price of the issuer's common stock on the grant date. The options are time-based and cliff vest in full on November 6, 2029, contingent on the reporting person's continued service through that date and compliance with the terms of the Plan and the applicable award agreement. The options expire on November 6, 2036. Prior to this grant, the filing reflects no pre-existing derivative security holdings for Solaiman, making the post-transaction count identical to the award size of 83,049 options, all held directly.

The filing was signed on November 9, 2026, by Justin Hunter on behalf of Shereen Solaiman. No non-derivative securities transactions were reported in Table I of this filing, and no amendment date was indicated, suggesting this is an original filing rather than a revision to a prior disclosure.

What Was Disclosed

The filing disclosed a retention-based grant of 83,049 non-qualified stock options to Myriad Genetics Chief People Officer Shereen Solaiman, with a $5.92 exercise price, full cliff vesting on November 6, 2029, and an expiration date of November 6, 2036.